JP2023524519A - 炎症性腸疾患の治療 - Google Patents

炎症性腸疾患の治療 Download PDF

Info

Publication number
JP2023524519A
JP2023524519A JP2022566661A JP2022566661A JP2023524519A JP 2023524519 A JP2023524519 A JP 2023524519A JP 2022566661 A JP2022566661 A JP 2022566661A JP 2022566661 A JP2022566661 A JP 2022566661A JP 2023524519 A JP2023524519 A JP 2023524519A
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524519A5 (enExample
Inventor
ハンス ヨハンソン，マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Aqilion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion AB filed Critical Aqilion AB
Publication of JP2023524519A publication Critical patent/JP2023524519A/ja
Publication of JP2023524519A5 publication Critical patent/JP2023524519A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022566661A 2020-04-30 2021-04-30 炎症性腸疾患の治療 Pending JP2023524519A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
GB2006390.5 2020-04-30
PCT/EP2021/061462 WO2021219879A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2023524519A true JP2023524519A (ja) 2023-06-12
JP2023524519A5 JP2023524519A5 (enExample) 2024-05-10

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566661A Pending JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療
JP2022566660A Active JP7702427B2 (ja) 2020-04-30 2021-04-30 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022566660A Active JP7702427B2 (ja) 2020-04-30 2021-04-30 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩

Country Status (9)

Country Link
US (2) US20230167064A1 (enExample)
EP (2) EP4142725A1 (enExample)
JP (2) JP2023524519A (enExample)
KR (2) KR20230018386A (enExample)
CN (2) CN115916200A (enExample)
AU (2) AU2021266154A1 (enExample)
CA (2) CA3177000A1 (enExample)
GB (2) GB202006390D0 (enExample)
WO (2) WO2021219879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171975A (en) * 1981-03-03 1982-10-22 Leo Ab Novel quinoline derivative and manufacture
JPH09510198A (ja) * 1994-03-10 1997-10-14 フアーマシア・アンド・アツプジヨン・アクチエボラーグ キノリン−３−カルボキシアミド化合物の新規な使用
JP2010523555A (ja) * 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
US20130005666A1 (en) * 2011-06-29 2013-01-03 Cornell University Reporter system for high throughput screening of compounds and uses thereof
JP2013500332A (ja) * 2009-07-30 2013-01-07 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
JP2013535437A (ja) * 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
JP2013543504A (ja) * 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5934202B2 (ja) * 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171975A (en) * 1981-03-03 1982-10-22 Leo Ab Novel quinoline derivative and manufacture
JPH09510198A (ja) * 1994-03-10 1997-10-14 フアーマシア・アンド・アツプジヨン・アクチエボラーグ キノリン−３−カルボキシアミド化合物の新規な使用
JP2010523555A (ja) * 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
JP2013500332A (ja) * 2009-07-30 2013-01-07 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
JP2013535437A (ja) * 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
JP2013543504A (ja) * 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド
US20130005666A1 (en) * 2011-06-29 2013-01-03 Cornell University Reporter system for high throughput screening of compounds and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FURUMATSU, K. ET AL.: "A Role of the Aryl Hydrocarbon Receptor in Attenuation of Colitis", DIGESTIVE DISEASES AND SCIENCES, vol. 56, no. 9, JPN6025017997, 2011, pages 2532 - 2544, ISSN: 0005587387 *
LARSEN，C. S. ET AL.: "Chapter 14 Design and application of prodrugs", TEXTBOOK OF DRUG DESIGN AND DISCOVERY, vol. Third edition, JPN7023001069, 2002, pages 460 - 514, ISSN: 0005587382 *
MAHIOUT, S. ET AL.: "In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators", TOXICOLOGY IN VITRO, vol. 52, JPN6025017991, 2018, pages 178 - 188, ISSN: 0005587381 *
QELLINY, M. R. ET AL.: "Colon Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease", JOURNAL OF ADVANCED BIOMEDICAL AND PHARMACEUTICAL SCIENCES, vol. 2, no. 4, JPN6025017999, 2019, pages 164 - 184, ISSN: 0005587388 *
SHRIDHAR, D. R.ET AL.: "Anti-inflammatory agents. Part II. Synthesis and anti-inflammatory activity of 3,4-disubstituted 2", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 17, no. 5, JPN6025017996, 1979, pages 488 - 90, ISSN: 0005587386 *
SIDORENKO, L. V. ET AL.: "Synthesis and antimycobacterial activity of trifluoromethyl-substituted anilides of 1-R-4-hydroxy-2-", FARMATSEVTICHNII ZHURNAL (KIEV, UKRAINE), vol. 1, JPN6025017993, 2009, pages 72 - 76, ISSN: 0005587384 *
UKRAINETS, I. V. ET AL.: "4-Hydroxy-2-quinolones. Part 110. Bromination of 1-R-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxyl", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 42, no. 10, JPN6025017992, 2006, pages 1301 - 1307, ISSN: 0005587383 *
UKRAINETS, I. V. ET AL.: "Synthesis and biological properties of 1-R-4-hydroxy-2-oxoquinoline-3-carboxylic acids 4'-hydroxyani", FARMATSEVTICHNII ZHURNAL (KIEV), vol. 6, JPN6025017995, 2001, pages 48 - 51, ISSN: 0005587385 *
高橋 俊雄、他, 今日のDDS・薬物送達システム, JPN6025017990, 25 December 1999 (1999-12-25), JP, pages 61 - 113, ISSN: 0005587389 *

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
US20230167064A1 (en) 2023-06-01
KR20230018386A (ko) 2023-02-07
CN115768429B (zh) 2024-02-09
GB202006390D0 (en) 2020-06-17
AU2021266154A1 (en) 2023-01-05
CN115916200A (zh) 2023-04-04
AU2021262514A1 (en) 2023-01-05
KR20230024892A (ko) 2023-02-21
EP4142725A1 (en) 2023-03-08
GB2605894A (en) 2022-10-19
CN115768429A (zh) 2023-03-07
WO2021219879A1 (en) 2021-11-04
JP2023524518A (ja) 2023-06-12
EP4142724A1 (en) 2023-03-08
US20230202982A1 (en) 2023-06-29
GB202207709D0 (en) 2022-07-06
GB2605894B (en) 2023-06-14
JP7702427B2 (ja) 2025-07-03
CA3177000A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
JP7358317B2 (ja) （３Ｓ，４Ｒ）－３－エチル－４－（３Ｈ－イミダゾ［１，２－ａ］ピロロ［２，３－ｅ］－ピラジン－８－イル）－Ｎ－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびそれの固体型の製造方法
EP0701819B1 (en) Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
EP2300430B1 (en) Benzene or thiophene derivative and use thereof as vap-1 inhibitor
CA2812034C (en) Methods for concomitant treatment of theophylline and febuxostat
KR20230024892A (ko) 염증성 장 질환의 치료
JP2010516694A (ja) 新規な伝統的葉酸拮抗剤
US8501738B2 (en) Substituted triazolo-pyridazine derivatives
US20240041836A1 (en) Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
CN102066379A (zh) 咪唑并[2，1-b]喹唑啉-2-酮衍生物及其作为血小板抗凝集剂的用途
JPH0141616B2 (enExample)
CN100372533C (zh) 腹泻为主大肠激惹综合征的治疗制剂
EP1973887B1 (en) Aza heterocyclics for the treatment of malaria or aids
JP2010536827A (ja) ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
RU2852858C2 (ru) Фармацевтическая композиция для предупреждения или лечения воспалительного заболевания кишечника, действующая в качестве функционального антагониста S1PR1 и S1PR4
CN1728998A (zh) 杂环胺类化合物作为神经保护剂的用途
JP5118648B2 (ja) 疾患の処置および予防のための組成物および方法
CN108358856B (zh) 一种防治消化性溃疡的药物以及其制备方法和用途
HK1082518A (en) Use of heterocyclic amine-type compounds as neuroprotective agents
JPH0827121A (ja) 新規なウラシル誘導体及びそれを有効成分とするアレルギ−疾患治療薬
JPS63284170A (ja) 新規グアニジノメチル−チオフエンカルボン酸誘導体
JPWO1996028164A1 (ja) 膵炎治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251203